A cross-over study of two oral contraceptive formulations, containing 30 μg ethinylestradiol
in combination with 150 μg desogestrel (Marvelon®) or 75 μg gestodene (Femovan®), has …

OBJECTIVE: A prospective, open-label, noncomparative, multicenter study was carried out
in 163 women aged 18–39 (mean 25±5 years), who used an ultra-low-dose oral …

Two low-dose oral contraceptives, both containing the same dose of ethinyl estradiol (EE2,
CAS 57-63-6) but different progestins--gestodene (CAS 60282-87-3) and desogestrel (CAS …

Ovulation inhibition by the monophasic oral contraceptive containing 75 μg of gestodene
and 30 wg of ethinyl estradiol was evaluated in 25 healthy volunteers for five cycles: a …

ABSTRACT A rapid and simple HPLC method for the determination of gestodene (GTD) and
ethinyl estradiol (ETE) in oral contraceptive formulations was developed and validated …

Objective To compare two oral contraceptive pills, both containing 150 μg desogestrel, but
with either 20 μg (Mercilon®) or 30 μg (Marvelon®/Desolett®) ethinyl oestradiol (EE) …

A randomized controlled clinical trial was undertaken over a 6-month treatment period with
two low-dose combined oral contraceptives (OC) to investigate whether the metabolism and …

Efficacy, cycle control, tolerance, and adverse events were studied in a clinical Phase IV
study using a new progestogen, gestodene, in an amount of 75 μg combined with 30 μg …

The time-dependent alterations in the serum concentrations of ethinyl estradiol, gestodene,
and 3-keto-desogestrel during treatment with 30 µg of ethinyl estradiol+ 75 µg of gestodene …

Since their introduction nearly 30 years ago, oral contraceptives have been widely
researched regarding their contraceptive and noncontraceptive effects. With proper usage …